Johnson & Johnson (NYSE:JNJ) Shares Sold by HC Advisors LLC

HC Advisors LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 14.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,808 shares of the company’s stock after selling 296 shares during the quarter. HC Advisors LLC’s holdings in Johnson & Johnson were worth $282,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC raised its holdings in Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares in the last quarter. Norges Bank acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $4,609,399,000. Capital International Investors grew its stake in Johnson & Johnson by 62.7% during the 2nd quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock worth $4,605,627,000 after buying an additional 10,724,110 shares during the last quarter. Journey Strategic Wealth LLC lifted its position in Johnson & Johnson by 161,420.2% in the 2nd quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock valued at $1,204,404,000 after purchasing an additional 7,271,978 shares during the last quarter. Finally, Morgan Stanley increased its stake in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the period. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $157.98 on Thursday. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The firm has a market cap of $380.30 billion, a PE ratio of 11.44, a P/E/G ratio of 2.62 and a beta of 0.53. The business has a fifty day simple moving average of $158.20 and a 200-day simple moving average of $159.04. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The business had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same quarter last year, the company posted $2.35 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a $1.19 dividend. The ex-dividend date is Friday, February 16th. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 24th. Finally, Barclays raised their price objective on shares of Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a research note on Thursday, October 12th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $176.14.

View Our Latest Report on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.